Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.29, $0.01 worse than the analyst estimate of $0.30. Revenue for the quarter came in at $116.9 million versus the consensus estimate of $116.17 million.

Emergent BioSolutions reaffirmed guidance.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.